Pharmac is asking for feedback on proposed changes to the access criteria for some funded medicines used to treat type 2 diabetes. Pharmac is proposing to change who can receive funded treatment with ...

This continuing education course details the role of GLP-1 injectables in managing chronic conditions and overweight/obesity, ...

Most participants treated with tirzepatide reported feeling "much more" hopeful, optimistic, happy, self-confident, and good about themselves compared how they felt with previous treatment. HealthDay ...

An analysis of patient-reported outcomes (PROs) from the SURPASS-SWITCH trial found that adults with type 2 diabetes who switched from dulaglutide to tirzepatide not only saw stronger improvements in ...

Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of ...

Treatment with dulaglutide, a GLP-1 receptor agonist, led to a substantial decrease in copeptin levels compared to that with placebo in participants with euvolaemia, independent of changes in blood ...

The SURPASS-CVOT trial—the large cardiovascular outcomes study that showed tirzepatide (Mounjaro) compared favorably with dulaglutide (Trulicity; both Eli Lilly) in patients with type 2 diabetes and ...

Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effects on glycemic control and body weight. The effects ...

No significant increase in hazard ratios seen for GI events for semaglutide versus dulaglutide, tirzepatide versus dulaglutide, tirzepatide versus semaglutide. (HealthDay News) — For patients with ...

Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of ...